ERBB2 and breast cancer: Research on the use of other AKT inhibitors, such as perifosine [163], afuresertib (GSK2110183), and uprosertib (GSK2141795), in HER2+ BC is limited, although some early studies have explored their potential in combination with HER2-targeted therapies.